Gibco™ CTS™ Immune Cell SR

Ref.: BL-RE-078077Manufacturer ref.: A2596102 250 ml
€1,820.00 excl. VAT

Anticipated Use: The CTS™ immune cell SR is designed to be used as a serum replacement in the cell culture and tissue of clinical samples. The product is intended for in vitro diagnosis.

Brand
Gibco

Anticipated Use: The CTS™ immune cell SR is designed to be used as a serum replacement in the cell culture and tissue of clinical samples. The product is intended for in vitro diagnosis.

Anticipated Use: The CTS™ immune cell SR is designed to be used as a serum replacement in the cell culture and tissue of clinical samples. The product is intended for in vitro diagnosis.

The replacement of serum (SR) of CTS™ immune cells is designed to promote the expansion of human immune cells grown in vitro such as T cells when added to a basic cell culture medium such as the SFM expansion of T cells CTS™ OpTmizer™ or the SFM CTS™ AIM-V™. The SR of CTS™ immune cells is a defined xeno-contaminant-free formulation and does not contain bovine or other non-human components derived from animals.

Minimizing the security and supply risks associated with human serum

Promotes the expansion of polyclonal T cells (microbead activated CD3 / CD28 T cells activated by OKT3 mAb, virus specific and tumour specific)

Supports T cell phenotype (CD4, CD8 and CD62L) similar to human serum

Promotes the expansion of gene-modified T CAR cells (lentioral transduction)

Reduces the costs and time spent on qualifying the eligible human serum

Sufficiently generic to be used with the basic media of your choice

Security of supply and security

The SR of CTS™ immune cells is a defined xeno-contaminant-free formulation that does not contain bovine or other non-human components derived from animals in the primary components. The site is FDA-approved and has an ISO13485 certified quality management system. The methods and controls used for manufacturing comply with current good manufacturing practices for medical devices, 21 CFR Part 820 of the Regulations. Full traceability documentation, such as the Certificate of Origin, Certificate of Analysis and Master Drug File, is available. The volume of the product can be adapted to meet future clinical and commercial needs. Other manufacturing sites are available to further reduce risks.

Qualified for T cells

The SR of CTS™ immune cells can replace human serum at similar concentrations and achieve similar performance. CTS™ immune cell SR promotes the expansion of polyclonal T cells (CD3 / CD28 activated by microbeads and TIL), T cell phenotypes (CD4, CD8 and CD62L) and the expansion of gene-modified T CAR cells (lentioral transduction). Each batch is pre-qualified in a functional assay of T cells using CD3 / CD28 CD28 CTS™ Dynabeads activated primary T cells to ensure constant performance. This reduces the costs and time spent testing human serum batches.

The CTS™ immune cell SR can replace human serum at similar concentrations without sacrificing performance in several different base media such as the TTS™ OpTmizer™ T-cell expansion SFM and the AIM-V™ CTS™ SFM or other commercial environments designed for immune cells. Variable SR dilutions of CTS™ immune cells should be tested to determine the optimal concentration required for your cell type and base medium.

The SR of CTS™ immune cells is available in a 50 ml vial for small volume users and in a 500 ml vial for larger volume users. For convenience, the product can be frozen and thawed once if smaller aliquots are required. CTS™ immune cell SR can be added to your standard base medium at concentrations similar to those of human serum.

Technical specifications

General
BrandGibco
Supplier ref. (Fisher Scientific)15463723

Origin and customs

Manufacturer ref.A2596102
Country of originUnited States
HS customs code3824 99 96 00
A question or a specific configuration?
Contact us for a quote.